Agios
Servier, Qiagen to Develop PCR-Based Companion Diagnostic to Identify IDH1-Mutant Leukemia
Qiagen will develop a real-time PCR-based in vitro diagnostic to identify patients eligible for Servier's Tibsovo and investigational IDH1-targeted agents.
Agios Pharmaceuticals, PerkinElmer Partner on Hereditary Anemia Genetic Testing Program
The next-generation sequencing-based panel comprises more than 50 genes and disorders known to cause hereditary anemias, such as pyruvate kinase deficiency.
Thermo Fisher Scientific, Agios Pharmaceuticals to Codevelop Glioma Companion Diagnostic
Thermo will develop a test using its Oncomine Precision Assay to identify IDH1- and IDH2-positive low-grade glioma patients for treatment with Agios' vorasidenib.
FDA Approves Abbott CDx, Agios Drug for AML Patients With IDH1 Mutation
This drug is the first FDA-approved IDH1 inhibitor and will be used to treat adult patients with relapsed or refractory acute myeloid leukemia.
Thermo Fisher, Agios Pharmaceuticals Strike CDx Partnership
The companies will work together on a next-generation sequencing-based companion diagnostic for Agios' investigational cancer drug ivosidenib.